Immunohistochemical Predictors of Bone Metastases in Breast Cancer Patients by unknown
RESEARCH
Immunohistochemical Predictors of Bone Metastases in Breast
Cancer Patients
Piotr Winczura1,6 & Katarzyna Sosińska-Mielcarek2 & Renata Duchnowska4 &
Andrzej Badzio1,6 & Joanna Lakomy1 & Hanna Majewska1 & Rafał Pęksa1 &
Beata Pieczyńska1 & Barbara Radecka3 & Sylwia Dębska-Szmich5 &
Krzysztof Adamowicz2 & Wojciech Biernat1 & Jacek Jassem1
Received: 16 February 2015 /Accepted: 26 May 2015 /Published online: 11 June 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Bones are the most common metastatic site of re-
lapse in breast cancer patients and the prediction of bone me-
tastases (BM) risk might prompt developing preventive and
therapeutic strategies. The aim of the study was to correlate
imumohistochemical (IHC) expression of selected proteins in
primary breast cancer with the occurrence of BM. We ana-
lyzed expression of proteins potentially associated with BM
in primary tumors of 184 patients with metastatic breast can-
cer (113 with- and 71 without BM). Expression of estrogen
receptor (ER) in primary tumor was more common in patients
with- compared to those without BM (74 vs. 45 % respective-
ly, p=0.0001), whereas in this subset less common was ex-
pression of parathyroid hormone related protein receptor type
1 (16 vs. 34 %, respectively, p=0.007) and cytoplasmic ex-
pression of osteopontin (OPNcyt; 1.9 vs. 14 %, respectively,
p=0.002). The relationship between expression of ER and
OPNcyt and the occurrence of BM was confirmed in the mul-
tivariate analysis. The ER-positive/OPNcyt negative pheno-
type was significantly more common in patients with- com-
pared to those without BM (75 and 25 %, p<0.0001,
respectively; HR 1.79, p=0.013). Luminal A (43 vs. 23 %
respectively, p=0.009) and luminal B/HER2-positive (16 vs.
4.9 % respectively, p=0.032) subtypes were more common in
patients with- compared to those without BM, whereas triple
negative breast cancer subtype was less common (16 vs. 38%,
p=0.002).
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factors . Immunohistochemistry
Introduction
Despite continuous progress in locoregional and systemic
therapies, substantial number of breast cancer patients experi-
ence relapse. Bones constitute the most common metastatic
site in advanced breast cancer, with the occurrence of up to
80 % [1, 2]. Patients with bone metastases (BM) have better
prognosis than those with visceral involvement, and some
may achieve long term survival. On the other hand, BM, due
to pain and pathological fractures, significantly affect quality
of life and remain a clinical challenge [1–3]. The development
of BM in breast cancer is a complex phenomenon and in-
cludes dynamic interaction between malignant cells and bone
tissue [4]. BM are typical for hormone receptor positive breast
cancers [5–7] Results of randomized studies using adjuvant
bisphosphonates to prevent BM in unselected groups of breast
cancer patients have been inconsistent [8, 9]. Molecular
markers facilitating individual risk assessment of BM might
be therefore clinically useful.
The aim of our study was to correlate imumohistochemical
(IHC) expression of selected proteins in primary breast cancer
with the occurrence of BM. The subject of this analysis were
four proteins routinely determined in breast cancer patients:
estrogen receptor (ER), progesterone receptor (PgR), human
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epidermal growth factor receptor 2 (HER2) and Ki67, and six
investigational proteins selected by their presumed association
with increased risk of BM: cyclooxygenase 2 (COX2) [10],
cytokeratins 5/6 (CK5/6) [5], chemokine receptor (CXCR4)
[11], parathyroid hormone related protein receptor type 1
(PTHrPR1) [12, 13], osteopontin (OPN) [14, 15] and calcium
sensing receptor (CaSR) [16].
Materials and Methods
Patient Population
The study was performed in 10 Polish oncology institutions
and was approved by the Ethics Committee of the coordinat-
ing center, theMedical University in Gdańsk. The study group
included 184 patients with metastatic breast cancer, including
113 patients with- and 71 without diagnosed BM (Table 1).
The diagnosis of BM was based on specific symptoms con-
firmed by imaging (X-ray, CT, MRI or bone scintigraphy) or
pathology. No screening for asymptomatic BM was per-
formed. The group with BM included also other locations of
metastatic disease (viscera, soft tissue). Notably, visceral me-
tastases were present in over 90 % of patients in the non-BM
group. Clinical data were extracted directly from the medical
charts.
Preparation of the Tissue Microarrays (TMA)
For each case, a pathologist identified representative tumor
area on paraffin fixed block, using a stained hematoxylin-
eosin section on a glass slide. From each block two tissue
cores of 1.5 mm were taken. Manual Tissue Arrayer
manufactured by Beecher Instruments (MTAI K7
Biosystems) was used for preparation of tissue microarrays.
Protein Expression
Expression of each protein was evaluated on stained 4 μm
sections. Characteristics of the antibodies used in the study
are presented in Table 2. Primary antibodies were incubated
according to manufacturer’s instructions and staining was per-
formed with the use of Novolink Polymer Detection System
by Novocastra.
For ER and PgR the staining was considered positive when
at least 1 % of tumor nuclei expressed the proteins [17]. HER2
expression was classified as positive (3+) if strong membra-
nous reaction was seen in more than 30 % of the invasive
cancer cells. In the case of equivocal staining (2+) fluorescent
in situ hybridization (FISH) data were taken from medical
charts, and if not available, FISH was performed using
TMA. FISH results were considered positive if HER2/
chromosome 17 centromere signals ratio was higher than 2.2
[18]. Ki67 immunostaining was considered high if ≥ 14 % of
the tumor nuclei stained positive [19, 20]. CK 5/6, tumors
were classified as positive if any membranous or cytoplasmic
staining was present [21]. Immunostaining for COX2 was
considered positive when moderate or strong cytoplasmic ex-
pression was present in ≥ 10 % tumor cells [22]. CXCR4
expression was assessed separately in the nucleus (CXCR4n)
and cytoplasm (CXCR4cyt), and staining in ≥ 1 % of the cells
was considered positive [23]. CaSR was assessed in the cyto-
plasm [16] and immunostaining was considered positive if









Mean age (range) 52 (30–78) 54 (30–83) 53 (30–83)
Menopausal status
- Premenopausal 51 (45 %) 26 (37 %) 77 (42 %)
- Postmenopausal 62 (55 %) 42 (59 %) 104 (57 %)
- Unknown 3 (4.2 %) 3 (1.6 %)
Histology
- Ductal 88 (78 %) 58 (82 %) 146 (79 %)
- Lobular 18 (16 %) 9 (13 %) 27 (15 %)
- Mixed
(ductal/lobular)
3 (2.7 %) 3 (4.2 %) 6 (3.3 %)
- Other types 4 (3.5 %) 1 (1.4 %) 5 (2.7 %)
Stage at diagnosis
- I 8 (7.1 %) 3 (4.3 %) 11 (6 %)
- II 51 (45 %) 32 (45 %) 83 (45 %)
- III 40 (35 %) 34 (49 %) 74 (41 %)
- IV 14 (12 %) 1 (1.4 %) 15 (8.2 %)





99 (88 %) 68 (96 %) 167 (91 %)
- Biopsy only 14 (12 %) 3 (4.2 %) 17 (9.2 %)
Radiotherapy
- Yes 100 (89 %) 47 (66 %) 147 (79 %)
- No/unknown 13 (11 %) 24 (34 %) 37 (21 %)
Chemotherapy
- Yes 102 (91 %) 66 (93 %) 168 (91 %)
- No/unknown 11 (9.4 %) 5 (6.5 %) 16 (8.7 %)
Hormonal therapy
- Yes 78 (69 %) 39 (55 %) 117 (63 %)
- No/unknown 35 (31 %) 32 (45 %) 67 (37 %)
Dominant site of metastasesa
- Bones 69 (61 %) 0 (0 %) 69 (38 %)
- Viscera 44 (39 %) 65 (91 %) 109 (59 %)
- Soft tissues 0 (0 %) 6 (8.5 %) 6 (3.5 %)
aDominant site of metastases refers to the metastatic site with the worst
prognosis
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moderate to strong reaction was seen in ≥ 50% of cancer cells.
For OPN and PTHrPR1 both cytoplasmic intensity (0 - no
staining, 1 - weak, 2 - moderate, 3 - strong) and percent of
stained cells (1 for ≤1%, 2 for >1–10%, 3 for >10–33%, 4 for
>33–66 %, 5 for >66 %) were assessed and summarized,
analogous to Allred score used for ER and PgR assessment.
The cutoff values for PTHrPR1 and OPNcyt were optimized at
>6 and >7, respectively, to maximize the hazard risk of bone
relapse between patients with expression levels above vs. be-
low the cutoff. For OPN the nuclear expression was addition-
ally assessed, and staining in ≥ 50 % of the cells was consid-
ered positive. Positive staining examples of CK 5/6, COX2,
OPN, PTHrPR1, CaSR and CXCR4 are shown in Fig. 1.
Based on the expression of ER, PgR, HER2 and Ki67, five
main breast cancer phenotypes were distinguished [19]. ER-
and/or PgR-positive, HER2-negative and Ki67-low tumors
were classified as luminal A, ER- and/or PgR-positive,
HER2-negative and Ki67 high - as luminal B/HER2-negative,
ER- and/or PgR-positive and HER2-positive - as luminal
B/HER2-positive, ER/PgR-negative and HER2-positive - as
nonluminal/HER2-positive, and ER-and/or PgR-negative and
HER2-negative - as triple negative.
Statistical Methods
STATA 8.0 software was used for statistical analyses. Cate-
gorical variables were compared using two-sided Pearson’s
chi-square test, and for small group samples Fisher exact test
was applied. Overall survival was estimated as time from ini-
tial pathological diagnosis to death and time to BM was the
time from initial pathological diagnosis to confirmation of BM
either with imaging or pathological examination. Overall sur-
vival and time to BM were calculated using Kaplan-Meier
method and differences were analyzed with log-rank test. Sta-
tistical significance was considered at p<0.05. To evaluate the
risk of BM, Cox proportional hazards regression was used.
Results
Median survival in the entire group was 48 months; 56 and
37 months in patients with- and without BM, respectively
(log-rank; p=0.0098, Fig. 2).
ER expression in primary tumor was present in 74 and
45 % of patients with- and without BM, respectively (p=
0.0001; Table 3). The respective figures for PgR were 55
and 42 % (p=0.096). There were no significant differences
in the occurrence of HER2 positivity (p=0.252) and high
Ki67 expression between both groups (p=0.13). CaSR was
overexpressed in most of the analyzed specimens; in 93 and
84 % of patients with- and without BM respectively (p=
0.053). OPNcyt expression was less common in patients
with- compared to those without BM (1.9 and 14 %, respec-
tively, p=0.002), whereas nuclear OPN (OPNn) expression
did not differ significantly between both groups (37 and
48 %, respectively, p=0.128). PTHrPR1 overexpression was
around twice less common in patients with- compared to those
without BM (16 and 34 %, respectively, p=0.007). COX2
expression was a common occurrence in both groups (88
and 79 % in patients with- and without BM, respectively,
p=0.148). CXCR4cyt was found in 87 and 90 % of patients
with- and without BM, respectively (p=0.74), and nuclear
CXCR4n—in 64 and 66%, respectively (p=0.92). Expression
of CK 5/6 was more common in triple negative breast cancer
subtype compared to all other subtypes combined (45 and
12 %, respectively, p=0.0001) and slightly less common in
subjects with- compared to those without BM (18 and 30 %,
respectively; p=0.066).
Multivariate analysis included proteins found to be signif-
icant (ER, PTHrPR1, OPNcyt) or of borderline significance
(CaSR and CK5/6) in univariate analysis. Of those, conserved
ER and absent OPNcyt proved to be independently associated
with the increased occurrence of BM (p=0.002 and p=0.018,
respectively).
Table 2 Antibodies used in the study
Protein Manufacturer Antigen retrieval Incubation time Dilution Method of evaluation
ER Novocastra,NCL-L-ER-6F11 HIERa (ph6) 1.5 h 1/400 Semi-quantitative
PgR Novocastra,NCL-L-PGR-312 HIER (ph6) 1.5 h 1/400 Semi-quantitative
HER2 Novocastra,NCL-L-CB11 HIER (ph9) 1.5 h 1/50 Semi-quantitative
Ki 67 Novocastra, NCL-L-Ki67-MM1 HIER (ph6) 1.5 h 1/1200 Semi-quantitative
OPN Abcam, ab 33046 HIER (ph6) 1.5 h 1/200 Semi-quantitative
CXCR4 Invitrogen, 358800 HIER (ph6) 1.5 h 1/25 Semi-quantitative
CaSR Pierce Bio., PA1-37213 HIER (ph6) 1.5 h 1/50 Semi-quantitative
COX2 Abcam, ab 10940 HIER (ph6) 1.5 h 1/100 Semi-quantitative
CK 5/6 Millipore, MAB1620 HIER (ph9) 1.5 h 1/400 Qualitative
PTHrPR1 Abcam, ab 3271 HIER (ph6) 1.5 h 1/50 Semi-quantitative
a HIER – heat induced epitope retrieval (in pressure cooker under 120 hPa for 2.5 min)
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The ER-positive/OPNcyt-negative phenotype was signifi-
cantly more common in BM compared to non-BM group
(75 and 25 %, p<0.0001, respectively; HR 1.79 [95 % CI
1.09–2.72]; p=0.013, Fig. 3).
Intrinsic molecular breast cancer surrogates could be deter-
mined in 160 subjects (87 %; Table 4). In the BM group the
most common subtype was luminal A (43 %), compared to
23 % in the non-BM group (p=0.009). Luminal B/HER2-
negative subtype constituted 15 and 21 % of cases in both
groups, respectively (p=0.32), and luminal B/HER2–positive
subtype - 16 and 4.9 %, respectively (p=0.032). There was no
significant difference in the occurrence of nonluminal/HER2-
positive subtype between both study groups (9.1 vs. 13 %,
respectively, p=0.42). Triple negative subtype was less com-
mon among patients with- compared to those without BM (16
and 38 %, respectively, p=0.002).
Discussion
Numerous studies investigated the predictive role of potential
novel biomarkers of BM in breast cancer, but their clinical
utility has not been established [12, 24, 25]. Our study showed
that expression of three proteins: ER, OPNcyt and PTHrPR1 in
Fig. 1 Representative images of
particular proteins’ expression
(magnification ×200). aCK5/6, b
CXCR4, c CaSR, d COX2, e
OPNn, f OPNcyt, g PTHrPR1
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primary breast cancers may be associated with increased
risk of BM. We also confirmed apparently different oc-
currence of BM in particular intrinsic breast cancer sur-
rogates. In concordance with other studies [6, 7], ER
positivity was associated with relatively high occurrence
and increased risk of BM. For PgR the trend was sim-
ilar, but the difference did not reach statistical signifi-
cance. The data on the association between PgR posi-
tivity and the occurrence of BM are inconsistent [7].
In our study CaSR was expressed in the vast majority of
patients and trended to be more pronounced in patients with
BM. Preclinical data suggest that CaSR stimulation can trig-
ger synthesis and secretion of PTHrP through EGFR path-
way [26]. PTHrP is also a key player in pathogenesis of
osteolytic metastases. Clinical data on the role of CaSR in
the development of BM in breast cancer patients are scarce,
however similar results were published by Mihai et al. [16].
Despite some differences between both studies, they provide
a strong signal of potential CaSR role in pathogenesis of
BM.
We hypothesized that high occurrence of BMmight also be
associated with expression of OPNcyt. OPN promotes
osteolysis by enabling adhesion of osteoclasts to the bone
matrix, and stimulates angiogenesis [14]. Animal studies sug-
gested that breast cancer cells expressing OPN have higher
prevalence to BM, particularly if they coexpress IL-11, anoth-
er potent osteolytic factor [24]. Other studies showed that
OPN stimulates progression of cancer and distant metastases
[27], and is an adverse prognostic factor [15]. We found sig-
nificantly lower occurrence of OPNcyt in patients with BM. To
our knowledge this is the first report on such relationship.
However, owing to small number of cases staining for OPNcyt,
our results should be interpreted cautiously. Apart from cyto-
plasmic staining, we also demonstrated less typical nuclear
expression of OPN. The biological role of such occurrence
is not well understood. Some studies demonstrated increased
nuclear content of this protein during cell division in S phase,
suggesting its role as a transcriptor factor involved in cell
proliferation [28].
In this series PTHrPR1 expression was less common in
patients with- compared to those without BM. Physiology of
PTHrPR1 is less understood than that of the corresponding
peptide (PTHrP). It is possible, that auto- and/or paracrine
stimulation of the receptor can lead to synthesis and secretion
of PTHrP, which in turn stimulates osteolysis. As mentioned
earlier, the whole process can be mediated by CaSR and
EGFR. A retrospective study by Hoey et al. [13] showed that
expression of PTHrPR1 is more common in BM compared to
Fig. 2 Overall survival of
patients with bone metastases
(n=113) and with extraskeletal
metastases (n=71)
Table 3 Expression of particular proteins in patients with- and without






ER 83 (74) 32 (45) 0.0001
PgR 62 (55) 29 (42) 0.096
HER2 25 (24) 11 (16) 0.252
Ki 67 36 (37) 31 (49) 0.13
CaSR 95 (93) 57 (84) 0.053
OPNn 38 (37) 31 (48) 0.128
OPNcyt 2 (1.9) 9 (14) 0.002
CXCR4cyt 91 (87) 60 (90) 0.74
CXCR4n 67 (64) 44 (66) 0.92
PTHrPR1 16 (16) 22 (34) 0.007
COX2 80 (79) 58 (88) 0.148
CK 5/6 19 (18) 21 (30) 0.066
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primary tumors. It was therefore postulated that expression of
PTHrPRmay be related to preponderance to BM. On the other
hand, some data indicate that PTHrPR expression can be stim-
ulated by the microenvironment of the metastatic cancer tissue
[13]. Expression of PTHrPR in primary breast cancer was
shown to be an adverse prognostic factor [12]. Indeed,
PTHrPR stimulation was postulated to promote cell prolifer-
ation, invasiveness [29] and angiogenesis [30].
Taken together, OPN and PTHrPR1 play an important role
in pathogenesis of BM in breast cancer patients but they are
also potent molecular factors involved in cancer progression
per se. This could potentially explain higher occurrence of
both proteins in primary tumors of patients with extraskeletal
metastases, where survival was worse.
Higher occurrence of ER–positivity and OPNcyt–negativity
in tumors that formed BM was confirmed in the multivariate
analysis. Notably, patients with ER–positive/OPNcyt–negative
phenotype had particularly high risk of BM. If confirmed in
further studies, this finding may prompt new preventive and
therapeutic strategies.
Consistent with other studies [5, 7], luminal A subtype was
found to be the most common phenotype in patients with BM.
Additionally, also luminal B/HER2-positive subtype was
more common in the BM group. Kennecke et al. [5] estimated
that the 15-year cumulative risk of BM in this latter subtype is
around 30 %, i.e., higher than in triple negative and luminal A
subtypes (16 and 18 %, respectively). Our results should be
treated with caution however, given a small number of luminal
B/HER2-positive cases. As expected, the extraskeletal metas-
tases (mostly visceral) were most common in the triple nega-
tive subset of patients.
Conclusion
Our study showed that ER expression and the absence of
OPNcyt expression are strong and independent factors
predicting increased risk of BM in breast cancer patients. Ad-
ditionally, BM occurrence was specifically associated with
luminal A and luminal/B HER2-positive subtypes.
We are aware that our study has several limitations. The
methods of IHC staining for investigational proteins may be
subjective, vary between particular studies and are not stan-
dardized. For most of the proteins we used previously devel-
oped scoring systems. The exceptions were CaSR and
PTHrPR1, for which we constructed our own scoring systems,
partially based on available literature. The obvious limitation
of our study is its retrospective nature. In consequence, the
non-BM group might have included patients with clinically
occult BM, missed in routine management. Further, BM diag-
nosis was determined using diagnostic methods with different
sensitivity (X-ray, CT, MRI, bone scintigraphy). Hence, inde-
pendent validation of our results is warranted to consider their
potential clinical relevance.
Fig. 3 Cumulative incidence of
bone metastases in patients with
ER-positive/OPNcyt-negative
immunohistochemical signature
vs. others. Excluded were 16
patients in whom the assessment
of either ER or OPN staining was
not possible
Table 4 Breast cancer phenotypes in patients with – and without BM








Luminal A 43 (43) 14 (23) 0.009
Luminal B HER2 (−) 15 (15) 13 (21) 0.32
Luminal B HER2 (+) 16 (16) 3 (4.9) 0.032
Nonluminal HER2 (+) 9 (9.1) 8 (13) 0.42
Triple negative 16 (16) 23 (38) 0.002
1234 P. Winczura et al.
Acknowledgments The authors would like to thank Dr J. Żok,
Dr M. Strzelecka, Dr M. Kulma-Kreft, Dr M.M. Litwiniuk, Dr E.
Jesień-Lewandowicz, Dr T. Rutkowski, Dr M. Jaworska-Jankowska and Dr
M. Foszczyńska-Kłoda for providing tumor samples for the study.
Funding This work was supported by a research grant from the Polish
Ministry of Science and Higher Education 2881/B/P01/2009/36.
Conflict of Interest The authors declare no conflict of interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Tubiana-Hulin M (1991) Incidence prevalence and distribution of
bone metastases. Bone (Suppl. 1):9–10
2. Coleman RE, Smith P, Rubens RD (1998) Clinical course and
prognostic factors following bone recurrence from breast cancer.
Br J Cancer 77:336–340
3. Plunkett TA, Smith P, Rubens RD (2000) Risk of complications
from bone metastases in breast cancer. Implications for manage-
ment. Eur J Cancer 36:476–482
4. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH,
Higgins LS et al (2006) Basic mechanisms responsible for
osteolytic and osteoblastic bone metastases. Clin Cancer Res 12:
6213–6216
5. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D,
Speers CH et al (2010) Metastatic behavior of breast cancer sub-
types. J Clin Oncol 28:3271–3277
6. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN (2003) Estrogen
receptors and distinct patterns of breast cancer relapse. Breast
Cancer Res Treat 78:105–118
7. Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K
et al (2011) Breast cancer biological subtypes and protein expres-
sion predict for the preferential distant metastasis sites: a nationwide
cohort study. Breast Cancer Res 13:R87
8. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G,
Heck D, Menzel C et al (2011) Adjuvant endocrine therapy
plus zoledronic acid in premenopausal women with early-
stage breast cancer: 62-month follow-up from the ABCSG-
12 randomised trial. Austrian Breast and Colorectal Cancer
Study Group, Vienna, Austria. Lancet Oncol 12:631–641
9. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R,
Keane M et al (2011) Breast cancer adjuvant therapy with zoledro-
nic acid. N Engl J Med 365:1396–1405
10. Singh B, Berry JA, Shoher A, Lucci A (2006) COX-2 induces IL-
11 production in human breast cancer cells. J Surg Res 131:267–
275
11. Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G et al
(2009) CXCR4 expression in early breast cancer and risk of distant
recurrence. Oncologist 14:1182–1188
12. Linforth R, Anderson N, Hoey R, Nolan T, Downey S, Brady G
et al (2002) Coexpression of parathyroid hormone related protein
and its receptor in early breast cancer predicts poor patient survival.
Clin Cancer Res 8:3172–3177
13. Hoey RP, Sanderson C, Iddon J, Brady G, Bundred NJ, Anderson NG
(2003) The parathyroid hormone-related protein receptor is expressed
in breast cancer bone metastases and promotes autocrine proliferation
in breast carcinoma cells. Br J Cancer 88:567–573
14. Asou Y, Rittling SR, Yoshitake H, Tsuji K, Shinomiya K, Nifuji A
et al (2001) Osteopontin facilitates angiogenesis, accumulation of
osteoclasts, and resorption in ectopic bone. Endocrinology 142:
1325–1332
15. Patani N, Jouhra F, JiangW, Mokbel K (2008) Osteopontin expres-
sion profiles predict pathological and clinical outcome in breast
cancer. Anticancer Res 28:4105–4110
16. Mihai R, Stevens J, McKinney C, IbrahimNB (2006) Expression of
the calcium receptor in human breast cancer—a potential new
marker predicting the risk of bone metastases. Eur J Surg Oncol
32:511–515
17. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL,
Badve S et al (2010) American Society of Clinical Oncology/
College of American Pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone recep-
tors in breast cancer (unabridged version). American Society of
Clinical Oncology; College of American Pathologists. Arch
Pathol Lab Med 134:48–72
18. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred
DC, Cote RJ et al (2007) American Society of Clinical
Oncology/College of American Pathologists guideline recom-
mendations for human epidermal growth factor receptor 2 test-
ing in breast cancer. American Society of Clinical Oncology/
College of American Pathologists. Arch Pathol Lab Med 131:
18–43
19. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B,
Senn HJ et al (2011) Strategies for subtypes—dealing with the
diversity of breast cancer: highlights of the St. Gallen
International Expert Consensus on the Primary Therapy of Early
Breast Cancer 2011. Ann Oncol 22:1736–1747
20. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC,
Cuzick J et al (2011) Assessment of Ki67 in breast cancer: recom-
mendations from the International Ki67 in Breast Cancer working
group. International Ki-67 in Breast Cancer Working Group. J Natl
Cancer Inst 103:1656–1664
21. Diallo-Danebrock R, Ting E, Gluz O, Herr A, Mohrmann S,
Geddert H et al (2007) Protein expression profiling in high-
risk breast cancer patients treated with high-dose or conven-
tional dose-dense chemotherapy. Clin Cancer Res 13:488–
497
22. Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund
C et al (2002) Prognostic significance of elevated cyclooxygenase-2
expression in breast cancer. J Cancer Res 62:632–635
23. Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Kodama R,
Sanke T et al (2008) Cytoplasmic CXCR4 expression in breast
cancer: induction by nitric oxide and correlation with lymph node
metastasis and poor prognosis. BMC Cancer 8:340
24. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM,
Cordón-Cardo C et al (2003) A multigenic program mediat-
ing breast cancer metastasis to bone. Cancer Cell 3:537–549
25. Ibrahim T, Sacanna E, Gaudio M, Mercatali L, Scarpi E, Zoli W
et al (2011) Role of RANK, RANKL, OPG, and CXCR4 tissue
markers in predicting bone metastases in breast cancer patients.
Clin Breast Cancer 11:369–375
26. MacLeod RJ, Yano S, Chattopadhyay N (2004) Extracellular
calcium-sensing receptor transactivates the epidermal growth factor
receptor by a triple-membrane-spanning signaling mechanism.
Biochem Biophys Res Commun 320:455–460
27. Craig AM, Bowden GT, Chambers AF, Spearman MA, Greenberg
AH, Wright JA et al (1990) Secreted phosphoprotein mRNA is
induced during multi-stage carcinogenesis in mouse skin and cor-
relates with the metastatic potential of murine fibroblasts. Int J
Cancer 46:133–137
Immunohistochemical predictors of bone metastases 1235
28. Junaid A, Moon MC, Harding GE, Zahradka P (2007) Osteopontin
localizes to the nucleus of 293 cells and associates with polo-like
kinase-1. Am J Physiol Cell Physiol 292:919–926
29. Luparello C, Burtis WJ, Raue F, Birch MA, Gallagher JA (1995)
Parathyroid hormone-related peptide and 8701-BC breast cancer
cell growth and invasion in vitro: evidence for growth-inhibiting
and invasion-promoting effects. Mol Cell Endocrinol 111:225–232
30. Akino K, Ohtsuru A, Kanda K, Yasuda A, Yamamoto T, Akino Y
et al (2000) Parathyroid hormone-related peptide is a potent tumor
angiogenic factor. Endocrinology 141:4313–4316
1236 P. Winczura et al.
